Experimental prostate cancer drug may improve COVID-19 survival ...United Arab Emirates

Gulf News - News
Experimental prostate cancer drug may improve COVID-19 survival
An experimental prostate cancer drug improved the survival of hospitalised COVID-19 patients in Brazil in a clinical trial, researchers reported on Tuesday on medRxiv ahead of peer review. The drug, proxalutamide being developed by Kintor Pharmaceuticals, blocks the effects of androgen hormones by inactivating their "receptors" on cell surfaces. Before the spikes on the surface of the coronavirus can break into cells and infect them, they must be "primed" by a protein called TMPRSS2, which is regulated by androgen receptors, explained study co-author John McCoy of Applied Biology Inc. In the Brazil trial, 645 hospitalised COVID-19 patients who were breathing on their own received either pro

Hence then, the article about experimental prostate cancer drug may improve covid 19 survival was published today ( ) and is available on Gulf News ( United Arab Emirates ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Experimental prostate cancer drug may improve COVID-19 survival )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News